| DB ID | MyCo_2581 |
| Title | Diagnosis of invasive aspergillosis in hematological malignancy patients: Performance of cytokines, Asp LFD, and Aspergillus PCR in same day blood and bronchoalveolar lavage samples |
| Year | 2018 |
| PMID | 29972764 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | Hematological Malignancy |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | The study protocol was approved by the local ethics committee, Medical University Graz, Austria (EC-numbers 25–221 and 23–343), and registered at ClinicalTrials.Gov (Identifier: NCT02058316 and NCT01576653). |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Bronchoalveolar lavage fluid (BALF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Austria |
| Cohort | In total 122 cases undergoing bronchoscopy were prospectively enrolled at the Medical University of Graz, Austria, between April 2014 and July 2017. Key inclusion criteria were i.) adult patients with ii.) underlying hematological malignancy who were iii.) at risk for IPA according to the attending clinicians (e.g. febrile neutropenia, induction chemotherapy for acute myeloid leukemia, allogeneic stem cell transplantation) and had iv.) a BALF sample obtained in clinical routine due to suspicion of infection. All patients who met inclusion criteria between April 2014 and July 2017 and signed an informed consent were included in the cohort. |
| Cohort No. | 122 |
| Age Group | None |
| P Value | None |
| Sensitivity | 0.23 |
| Specificity | 0.92 |
| Positive Predictive Value | 0.67 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive mold infections (IMI) including invasive aspergillosis (IA) are associated with high morbidity and mortality among patients with underlying hematological malignancies. Mycological diagnosis is challenging, with cultures of bronchoalveolar lavage fluid (BALF) having a low sensitivity. Consequently, fungal biomarkers such as galactomannan [GM], beta-D-glucan [BDG] and also molecular diagnostic tests (polymerase chain reaction [PCR]) of blood or BALF, have emerged and are now widely used for diagnosing IA. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | Platelia™ Aspergillus Ag Kit (BioRad, Hercules, CA, USA) |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | GM-Platelia™ Aspergillus Ag ELISA, FDA approved Fungitell assay,Aspergillus PCR |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
